Tao An
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tao An has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Baiqiang Cai
Department of Respiratory Medicine and
1 shared publication- Binghe Xu
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication - Binliang Liu
Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha Hunan China
1 shared publication - Chao Wu
Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; State Key Laboratory of Cardiovascular Disease, Beijing, China; National Clinical Research Center for Cardiovascular Diseases, Beijing, China
1 shared publication Chunxiao Li
Chinese Academy of Medical Sciences and Peking Union Medical College
1 shared publication- Fei Ma
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
1 shared publication
Latest Publications
- Open Access
- 10 March 2026
- Published by Wolters Kluwer Health in Asian Heart Journal
- Vol. 2 (1) , 59-67
Aspirin-free strategy after short-term dual antiplatelet therapy in patients with complex percutaneous coronary intervention: A systematic review and network meta-analysis
Objectives: The transition from short dual antiplatelet therapy (DAPT) to P2Y 12 inhibitor monotherapy has recently gained popularity as a strategy to reduce aspirin-related bleeding while preserving the antithrombotic benefit of DAPT. However, the safety and efficacy of P2Y 12 inhibitor monotherapy after short-term DAPT in patients who received complex percutaneous coronary intervention (PCI) remains uncertain. Methods: The PubMed, EMBASE, Cochrane Library, and Web of Science were searched to identify randomized controlled trials published in any language between January 1980 and June 2023. Only peer-reviewed articles and randomized controlled trials were included. The primary efficacy and safety endpoints were major adverse cardiovascular events and major bleeding. We divided antiplatelet strategies into three categories based on previous clinical trials: P2Y 12 inhibitor monotherapy after 1 or 3 months DAPT, aspirin monotherapy after 3 or 6 months DAPT, and aspirin monotherapy after long-term (≥12 months) DAPT. The network meta-analysis was performed by the frequentist approach (PROSPERO-ID CRD42020192256). Results: Nine studies involving 16,201 patients with complex PCI were included. Within 1 year after complex PCI, the pooled results showed that compared with long-term DAPT, 1 or 3 months DAPT followed by P2Y 12 inhibitor monotherapy could significantly reduce the risk of primary efficacy endpoint (hazard ratio [HR], 0.67; 95% confidence interval [CI]: 0.52–0.87) as well as the risk of all-cause mortality (HR, 0.55; 95% CI, 0.37–0.81), target vessel revascularization (HR, 0.60; 95% CI, 0.45–0.79), and any bleeding events (HR, 0.52; 95% CI, 0.38–0.73). The indirect comparison revealed that P2Y 12 inhibitor monotherapy was correlated with a lower risk of major adverse cardiovascular events (HR, 0.44; 95% CI, 0.27–0.71), myocardial infarction (HR, 0.50; 95% CI, 0.28–0.90), and target vessel revascularization (HR, 0.61; 95% CI, 0.37–0.98) at 12 months compared with aspirin monotherapy after 3 or 6 months DAPT. Beyond 12 months, there were no significant differences in terms of major adverse cardiovascular events among these three antiplatelet treatments, while major bleeding (HR, 0.37; 95% CI, 0.14–0.94) resulted significantly lower, adopting an aspirin monotherapy strategy compared with prolonged DAPT. Conclusion: For patients with complex PCI, early discontinuation of DAPT to P2Y 12 inhibitor monotherapy might be a safer and equally effective strategy compared with aspirin monotherapy after 3 or 6 months or long-term DAPT.
- 10 March 2026
- Published by Wolters Kluwer Health in Asian Heart Journal
- Vol. 2 (1) , 59-67
Open AccessAspirin-free strategy after short-term dual antiplatelet therapy in patients with complex percutaneous coronary intervention: A systematic review and network meta-analysis
Objectives: The transition from short dual antiplatelet therapy (DAPT) to P2Y 12 inhibitor monotherapy has recently gained popularity as a strategy to reduce aspirin-related bleeding while preserving the antithrombotic benefit of DAPT. However, the safety and efficacy of P2Y 12 inhibitor monotherapy after short-term DAPT in patients who received complex percutaneous coronary intervention (PCI) remains uncertain. Methods: The PubMed, EMBASE, Cochrane Library, and Web of Science were searched to identify randomized controlled trials published in any language between January 1980 and June 2023. Only peer-reviewed articles and randomized controlled trials were included. The primary efficacy and safety endpoints were major adverse cardiovascular events and major bleeding. We divided antiplatelet strategies into three categories based on previous clinical trials: P2Y 12 inhibitor monotherapy after 1 or 3 months DAPT, aspirin monotherapy after 3 or 6 months DAPT, and aspirin monotherapy after long-term (≥12 months) DAPT. The network meta-analysis was performed by the frequentist approach (PROSPERO-ID CRD42020192256). Results: Nine studies involving 16,201 patients with complex PCI were included. Within 1 year after complex PCI, the pooled results showed that compared with long-term DAPT, 1 or 3 months DAPT followed by P2Y 12 inhibitor monotherapy could significantly reduce the risk of primary efficacy endpoint (hazard ratio [HR], 0.67; 95% confidence interval [CI]: 0.52–0.87) as well as the risk of all-cause mortality (HR, 0.55; 95% CI, 0.37–0.81), target vessel revascularization (HR, 0.60; 95% CI, 0.45–0.79), and any bleeding events (HR, 0.52; 95% CI, 0.38–0.73). The indirect comparison revealed that P2Y 12 inhibitor monotherapy was correlated with a lower risk of major adverse cardiovascular events (HR, 0.44; 95% CI, 0.27–0.71), myocardial infarction (HR, 0.50; 95% CI, 0.28–0.90), and target vessel revascularization (HR, 0.61; 95% CI, 0.37–0.98) at 12 months compared with aspirin monotherapy after 3 or 6 months DAPT. Beyond 12 months, there were no significant differences in terms of major adverse cardiovascular events among these three antiplatelet treatments, while major bleeding (HR, 0.37; 95% CI, 0.14–0.94) resulted significantly lower, adopting an aspirin monotherapy strategy compared with prolonged DAPT. Conclusion: For patients with complex PCI, early discontinuation of DAPT to P2Y 12 inhibitor monotherapy might be a safer and equally effective strategy compared with aspirin monotherapy after 3 or 6 months or long-term DAPT.
- Open Access
- 26 July 2023
- Published by Springer Nature in Current Cardiology Reports
- Vol. 25 (8) , 863-878
Cardio-oncology: Shared Genetic, Metabolic, and Pharmacologic Mechanism
Purpose of Review: The article aims to investigate the complex relationship between cancer and cardiovascular disease (CVD), with a focus on the effects of cancer treatment on cardiac health. Recent Findings: Advances in cancer treatment have improved long-term survival rates, but CVD has emerged as a leading cause of morbidity and mortality in cancer patients. The interplay between cancer itself, treatment methods, homeostatic changes, and lifestyle modifications contributes to this comorbidity. Recent research in the field of cardio-oncology has revealed common genetic mutations, risk factors, and metabolic features associated with the co-occurrence of cancer and CVD. Summary: This article provides a comprehensive review of the latest research in cardio-oncology, including common genetic mutations, risk factors, and metabolic features, and explores the interactions between cancer treatment and CVD drugs, proposing novel approaches for the management of cancer and CVD.
- 26 July 2023
- Published by Springer Nature in Current Cardiology Reports
- Vol. 25 (8) , 863-878
Open AccessCardio-oncology: Shared Genetic, Metabolic, and Pharmacologic Mechanism
Purpose of Review: The article aims to investigate the complex relationship between cancer and cardiovascular disease (CVD), with a focus on the effects of cancer treatment on cardiac health. Recent Findings: Advances in cancer treatment have improved long-term survival rates, but CVD has emerged as a leading cause of morbidity and mortality in cancer patients. The interplay between cancer itself, treatment methods, homeostatic changes, and lifestyle modifications contributes to this comorbidity. Recent research in the field of cardio-oncology has revealed common genetic mutations, risk factors, and metabolic features associated with the co-occurrence of cancer and CVD. Summary: This article provides a comprehensive review of the latest research in cardio-oncology, including common genetic mutations, risk factors, and metabolic features, and explores the interactions between cancer treatment and CVD drugs, proposing novel approaches for the management of cancer and CVD.
- 6 January 2021
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 14 (4) , 598-609
Angiographic Scoring System for Predicting Successful Percutaneous Coronary Intervention of In-Stent Chronic Total Occlusion
The purpose of this study was to develop a scoring model to predict the technical success of recanalizing via antegrade approach in-stent chronic total occlusion (IS-CTO) by percutaneous coronary intervention (PCI). We retrospectively collected data from 474 patients who underwent an uneasy IS-CTO PCI via antegrade approach from January 2015 to December 2018, consecutively. We selected clinical and angiographic factors and utilized a derivation and validation cohort (4:1 sampling ratio) analysis. Factors with strong correlations with technical failure, according to multivariable analysis, were assigned 1 point, and a scoring system with a 4-point maximum was established. The model was then validated with a validation cohort. The overall procedural success rate was 77.4%. On multivariable analysis, the factors that correlated with technical failure were proximal bending (beta coefficient [β] = 2.142), tortuosity (β = 2.622), stent under expansion (β = 3.052), and poor distal landing zone (β = 2.004). The IS-CTO score demonstrated good calibration and excellent predicting capacity in the derivation (receiver-operator characteristic [ROC] area = 0.973 and Hosmer-Lemeshow chi-squared = 5.252; p = 0.072) and validation (ROC area = 0.976 and Hosmer-Lemeshow chi-squared = 0.916; p = 0.632) cohorts. In the validation subset, the IS-CTO score demonstrated superior performance to the Japanese chronic total occlusion score (J-CTO) and PROGRESS CTO scores for predicting technical success (area under the a curve [AUC] 0.976 vs. 0.642 vs. 0.579, respectively; difference in AUC between the IS-CTO score and J-CTO score = 0.334, p < 0.01; difference in AUC between the IS-CTO score and PROGRESS score = 0.397, p < 0.01). Our results suggest that the IS-CTO score system is a helpful tool to predict the technical success of IS-CTO PCI via antegrade approach in china. Graphical Abstract
- 6 January 2021
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 14 (4) , 598-609
Angiographic Scoring System for Predicting Successful Percutaneous Coronary Intervention of In-Stent Chronic Total Occlusion
The purpose of this study was to develop a scoring model to predict the technical success of recanalizing via antegrade approach in-stent chronic total occlusion (IS-CTO) by percutaneous coronary intervention (PCI). We retrospectively collected data from 474 patients who underwent an uneasy IS-CTO PCI via antegrade approach from January 2015 to December 2018, consecutively. We selected clinical and angiographic factors and utilized a derivation and validation cohort (4:1 sampling ratio) analysis. Factors with strong correlations with technical failure, according to multivariable analysis, were assigned 1 point, and a scoring system with a 4-point maximum was established. The model was then validated with a validation cohort. The overall procedural success rate was 77.4%. On multivariable analysis, the factors that correlated with technical failure were proximal bending (beta coefficient [β] = 2.142), tortuosity (β = 2.622), stent under expansion (β = 3.052), and poor distal landing zone (β = 2.004). The IS-CTO score demonstrated good calibration and excellent predicting capacity in the derivation (receiver-operator characteristic [ROC] area = 0.973 and Hosmer-Lemeshow chi-squared = 5.252; p = 0.072) and validation (ROC area = 0.976 and Hosmer-Lemeshow chi-squared = 0.916; p = 0.632) cohorts. In the validation subset, the IS-CTO score demonstrated superior performance to the Japanese chronic total occlusion score (J-CTO) and PROGRESS CTO scores for predicting technical success (area under the a curve [AUC] 0.976 vs. 0.642 vs. 0.579, respectively; difference in AUC between the IS-CTO score and J-CTO score = 0.334, p < 0.01; difference in AUC between the IS-CTO score and PROGRESS score = 0.397, p < 0.01). Our results suggest that the IS-CTO score system is a helpful tool to predict the technical success of IS-CTO PCI via antegrade approach in china. Graphical Abstract
- Open Access
- 4 December 2018
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 38 (1) , 71
The association between early‐onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple‐negative breast cancer patients and some novel autophagy‐related polymorphisms in their genomic DNA: a real‐world study
Background: An increasing number of cancer patients die of cardiovascular diseases. The cardiotoxicity of chemotherapy is particularly important in triple‐negative breast cancer (TNBC) with limited therapeutic options. Cardiac autophagy is an important mechanism of cardiotoxicity. This research was aimed to investigate the cardiotoxicity of chemotherapy in TNBC, screen the susceptible population, and determine the relationship between cardiotoxicity and autophagy‐related polymorphisms. Methods: From a total of 2450 stage I‐III TNBC patients, 147 met the inclusion criteria and finally recruited. Electrocardiography (ECG) was performed before most chemotherapy cycles, and echocardiography (UCG) was performed according to clinical needs. All ECG and UCG records were re‐interpreted by cardiologists at the National Center for Cardiovascular Disease, Fuwai Hospital. According to the National Center for Biotechnology Information and the Catalog of Somatic Mutations in Cancer database, we selected 25 single nucleotide polymorphisms (SNPs) related to autophagy and genotyped the 147 TNBC patients. Paired‐sample T tests, Chi squared tests, and logistic regression models were employed for the analysis. Results: Only 46 (31.3%) patients had normal ECG records after every chemotherapy cycle. Among the 16 patients who underwent UCG, 2 (12.5%) had a reversible decrease of left ventricular ejection fraction. The use of anthracyclines and excessive alcohol consumption were risk factors of ECG abnormalities. With the continuation of chemotherapy, heart rate gradually increased. Anthracyclines were associated with QRS duration abnormalities ( P = 0.043). After genotyping for 25 autophagy‐related SNPs, we found that the G allele of autophagy‐related 13 ( ATG13 ) rs10838611 was significantly associated with ECG abnormalities (odds ratio = 2.258, 95% confidence interval = 1.318–3.869; P = 0.003). Conclusion: ECG abnormalities caused by chemotherapy are common in the real world. Autophagy‐related SNPs are associated with chemotherapy‐induced cardiotoxicity, thereby providing new evidence for autophagy as a cause of chemotherapy‐induced cardiac damage.
- 4 December 2018
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 38 (1) , 71
Open AccessThe association between early‐onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple‐negative breast cancer patients and some novel autophagy‐related polymorphisms in their genomic DNA: a real‐world study
Background: An increasing number of cancer patients die of cardiovascular diseases. The cardiotoxicity of chemotherapy is particularly important in triple‐negative breast cancer (TNBC) with limited therapeutic options. Cardiac autophagy is an important mechanism of cardiotoxicity. This research was aimed to investigate the cardiotoxicity of chemotherapy in TNBC, screen the susceptible population, and determine the relationship between cardiotoxicity and autophagy‐related polymorphisms. Methods: From a total of 2450 stage I‐III TNBC patients, 147 met the inclusion criteria and finally recruited. Electrocardiography (ECG) was performed before most chemotherapy cycles, and echocardiography (UCG) was performed according to clinical needs. All ECG and UCG records were re‐interpreted by cardiologists at the National Center for Cardiovascular Disease, Fuwai Hospital. According to the National Center for Biotechnology Information and the Catalog of Somatic Mutations in Cancer database, we selected 25 single nucleotide polymorphisms (SNPs) related to autophagy and genotyped the 147 TNBC patients. Paired‐sample T tests, Chi squared tests, and logistic regression models were employed for the analysis. Results: Only 46 (31.3%) patients had normal ECG records after every chemotherapy cycle. Among the 16 patients who underwent UCG, 2 (12.5%) had a reversible decrease of left ventricular ejection fraction. The use of anthracyclines and excessive alcohol consumption were risk factors of ECG abnormalities. With the continuation of chemotherapy, heart rate gradually increased. Anthracyclines were associated with QRS duration abnormalities ( P = 0.043). After genotyping for 25 autophagy‐related SNPs, we found that the G allele of autophagy‐related 13 ( ATG13 ) rs10838611 was significantly associated with ECG abnormalities (odds ratio = 2.258, 95% confidence interval = 1.318–3.869; P = 0.003). Conclusion: ECG abnormalities caused by chemotherapy are common in the real world. Autophagy‐related SNPs are associated with chemotherapy‐induced cardiotoxicity, thereby providing new evidence for autophagy as a cause of chemotherapy‐induced cardiac damage.
- 15 December 2016
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 194 (12) , e17-e18
Esophagus-like Bronchus in an Adult with Common Variable Immunodeficiency Disease
- 15 December 2016
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 194 (12) , e17-e18
Esophagus-like Bronchus in an Adult with Common Variable Immunodeficiency Disease